WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Vibrant festival highlights cultural charm of various Chinese ethnic groupsGiant panda parents, cubs back in China from SpainANDREW PIERCE: Will Keir criticism see Mandy back in the wilderness?China's top political advisory body starts annual sessionForeign trade set to stay resilient this yearPolish voters choose mayors in hundreds of cities in runoff electionOil consumption back to 2019 levelsMusgrove goes 7 innings and Bogaerts homers as the Padres beat the Blue Jays 6Vietnam police arrest assistant to National Assembly chairman — Radio Free AsiaJingdezhen ceramics shine bright under BRI
2.231s , 6505.2890625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Cultural Caravan news portal